Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EryDel S.p.A.
Bresso (Milan), Italyerydel.com ↗
- Ownership
- Private
- Employees
- ~21
- Development stage
- Other
01
Overview
EryDel's lead product EryDex is in Phase 3 development for Ataxia-Telangiectasia, a rare neurodegenerative disease with no approved treatments. The technology encapsulates dexamethasone sodium phosphate in the patient's own red blood cells for sustained therapeutic delivery over a monthly treatment period.
- Therapeutic areas
- Neurology
- Modalities
- Red blood cell-based drug delivery
- Industry
- Biotech
Beyond the preview
Go deeper on EryDel S.p.A..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EryDel S.p.A..